Raising the Minimum Effective Dose of Serotonin Reuptake Inhibitor Antidepressants: Adverse Drug Events
The DOI matches its Crossref record; 185 of the 185 references it cites were found in a registry or an index.
Abstract
This review focuses on the dose-response of serotonin reuptake inhibitor (SRI) antidepressants for efficacy and for adverse drug events (ADEs). Dose-response is identified by placebo-controlled, double-blind, fixed-dose clinical trials comparing various doses for efficacy and for ADEs. Reports from the great majority of clinical trials have consistently found that the minimum SRI effective dose is usually optimal for efficacy in the treatment of depression disorders, even though most American medical practitioners raise the dose when early antidepressant treatment results are negative or partial. To better understand this issue, the medical literature was comprehensively reviewed to ascertain the degree to which SRI medications resulted in a flat dose response for efficacy and then to identify specific ADEs that are dose-dependent. Strong evidence from fixed-dose trial data for the efficacy of nonascendant, minimum effective doses of SRIs was found for the treatment of both major depression and anxiety disorders. Particularly important was the finding that most SRI ADEs have an ascending dose-response curve. These ADEs include sexual dysfunction, hypertension, cardiac conduction risks, hyperglycemia, decreased bone density, sweating, withdrawal symptoms, and agitation. Thus, routinely raising the SRI dose above the minimum effective dose for efficacy can be counter-productive.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Adverse events, in contrast, may have an ascending dose-response curve [4, 47], presumably due to co-affinity to other receptors.”
From The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review (2022) · cites this paper as [47]
Citations
Cites
Drugs and Falls in Older People: A Systematic Review and Meta‐analysis: I. Psychotropic Drugs
Leipzig, R. M., Cumming, R. G., & Tinetti, M. E. (1999) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1999.tb01898.x · Cited by 1,153
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
Treatment-Emergent Sexual Dysfunction Related to Antidepressants: A Meta-Analysis
Serretti, A., & Chiesa, A. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181a5233f · Cited by 583
Dimensions of the Beck depression inventory-II in clinically depressed outpatients
Steer, R. A., Ball, R., Ranieri, W. F., & Beck, A. T. (1999) · Journal of Clinical Psychology · doi:10.1002/(sici)1097-4679(199901)55:1<117::aid-jclp12>3.0.co;2-a · Cited by 577
Meyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517 · cited 2×
“In addition to data from a range of fixed-dose clinical trials which show optimal SRI efficacy at the minimum effective dose, linked serotonin transporter studies reveal near maximum (70%-80%) platelet serotonin transporter occupancy inhibition at various doses.(5,83,88) This provides specific biomarker data that supp…”
BackgroundShea, M. T. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820100026006 · Cited by 509
Montejo-gonzàlez, A. L., Llorca, G., Izquierdo, J. A., Ledesma, A., Bousono, M., Calcedo, A., Carrasco, J. L., Ciudad, J., Daniel, E., De LA Gandara, J., et al. (1997) · Journal of Sex & Marital Therapy · doi:10.1080/00926239708403923 · Cited by 505
Antidepressant use in persons aged 12 and over: United States, 2005-2008.
Pratt, L. A., Brody, D. J., & Gu, Q. (2011) · PubMed · Cited by 490
Relative Toxicity of Selective Serotonin Reuptake Inhibitors (SSRIs) in Overdose
Isbister, G. K., Bowe, S. J., Dawson, A., & Whyte, I. M. (2004) · Journal of Toxicology: Clinical Toxicology · doi:10.1081/clt-120037428 · Cited by 435
Efficacy and Safety of Paroxetine Treatment for Chronic PTSD: A Fixed-Dose, Placebo-Controlled Study
Marshall, R. D., Beebe, K. L., Oldham, M., & Zaninelli, R. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.12.1982 · Cited by 432
Research works printed but not linked: 5
- 2014, Levomilnacipran inhibits both norepinephrine and serotonin reuptake across the clinical dose range, Eur Neuropsychopharmacol, 24, S459
- 1992, Serotonergic antidepressants and their efficacy in obsessive compulsive disorder, J Clin Psychiatry, 53, 56
- 2014, Effect of SSRIs on bone metabolism, Encephale, 40, 56
- 1990, Fluoxetine: relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression, Psychopharmacol Bull, 26, 18
- 1983, Clinical evaluation and natural course of depression, J Clin Psychiatry, 44, 5
Cited by
Bousman, C. A., Stevenson, J. M., Ramsey, L. B., Sangkuhl, K., Hicks, J. K., Strawn, J. R., Singh, A. B., Ruaño, G., Mueller, D. J., Tsermpini, E. E., et al. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2903 · Cited by 521
Sørensen, A., Ruhé, H. G., & Munkholm, K. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01285-w · Cited by 65
Metadata
- Authors
- Safer, D. J.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Safer, Daniel J.
- ORCID
- Safer, Daniel J.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2016-10
- Volume
- 36
- Issue
- 5
- Pages
- 483-491
- ISSN
- 0271-0749 (ISSN-L)
- 1533-712X
- OpenAlex
- W2518204736
- Cited by
- 19
- References
- 185
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 1 · 2023: 2 · 2022: 1 · 2021: 4 · 2020: 1 · 2019: 3 · 2018: 1 · 2017: 3
- FWCI
- 0.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- serotonin reuptake inhibitors, minimum effective dose, dose escalation, adverse drug reactions, depression, anxiety disorders, sexual dysfunction, hypertension, cardiac conduction, hyperglycemia, bone mineral density, withdrawal symptoms, agitation
- MeSH terms
- Dose-Response Relationship, Drug, Humans, Selective Serotonin Reuptake Inhibitors, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Raising the Minimum Effective Dose of Serotonin Reuptake Inhibitor Antidepressants: Adverse Drug Events. https://app.cochat.ai/papers/10.1097/jcp.0000000000000564
- The paper
- Safer, D. J. (2016). Raising the Minimum Effective Dose of Serotonin Reuptake Inhibitor Antidepressants: Adverse Drug Events. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0000000000000564
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.